Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 375 participants.

Also called NCT01257412

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 375 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01257412
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
India (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT01257412. Randomized; quadruple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01257412
Content hash
fb70f9159b4881e3fae3ff83bda9ba3449578d6179dead8d5fa88184d8bc13b4